Oncology

Latest News

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

By Pearl Steinzor

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com

Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

By Pearl Steinzor

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com

Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

By Rose McNulty

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

July 24th 2015

Computational Approach Relates Gene Signatures With Cancer Outcomes

AJMC Staff

A study published in Nature Medicine has identified a gene signature that can predict cancer patient outcomes across a wide spectrum of malignancies.

July 24th 2015

Will Drug Costs Be the Big Political Issue of 2016?

Mary K. Caffrey

Recent surveys have found that public sentiment on drug costs runs high and crosses the political divide. A move this week by the nation's leading oncologists to rein in therapy pricing may be a sign that this is the breakthrough issue of the presidential campaign.

July 23rd 2015

Need for Palliative Care for Improved Performance at the End of Life

AJMC Staff

A study in JAMA Oncology has found that chemotherapy for patients with end-stage cancer was associated with worse quality of life near death while they still retained their ability to perform many life functions.

July 23rd 2015

JCO Study Concludes Improved Care and Treatment Options Responsible for Breast Cancer Survival

Surabhi Dangi-Garimella, PhD

While the study found differences in hazard ratio for age-specific survival, improved care and better treatment options might have resulted in increased survival, the authors deduce.

July 22nd 2015

Advances in Precision Medicine, Discussions on "Value" Highlight Special Issue on 2015 ASCO Meeting

A special issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care, covers clinical sessions, updates on new trial designs, and coverage of the discussion of "value" in cancer care from the 2015 meeting of the American Society of Clinical Oncology. The meeting took place May 29 to June 2, 2015, at Chicago's McCormick Convention Center.

July 22nd 2015

ASCO Releases Clinical Practical Guidelines for Decisions on Systemic Therapy for Metastatic Breast Cancer

Surabhi Dangi-Garimella, PhD

ASCO's Breast Cancer Guideline Advisory Group and Clinical Practice Guideline Committee have published an updated guideline in the Journal of Clinical Oncology on using breast cancer biomarkers to guide clinical decisions when treating advanced metastatic breast cancer.

July 22nd 2015

AJMC Staff

Zarxio (filgrastim-sndz), manufactured by Sandoz as a biosimilar to Amgen's Neupogen, has finally received marketing approval from a federal appeals court.

July 22nd 2015

Following Nivolumab, Pembrolizumab Receives EU Approval as First-Line for Melanoma

Surabhi Dangi-Garimella, PhD

Merck (MSD) has announced that its PD-1 inhibitor pembrolizumab (Keytruda) was approved by the European Commission for the treatment of advanced (unresectable or metastatic) melanoma in adults.

July 21st 2015

SGLT2 Inhibitors Can Reduce Tumor Growth

Surabhi Dangi-Garimella, PhD

Researchers at UCLA have discovered that inhibiting SGLT2 in pancreatic and prostate adenocarcinomas can reduce cancer cell survival.

July 20th 2015

ASCO Calls for Developing Oncology Trials for Geriatric Patients

AJMC Staff

The American Society of Clinical Oncology has issued a position statement in the Journal of Clinical Oncology, calling for federal agencies and the cancer research community to broaden clinical trials to include older adults.

July 20th 2015

CMS Testing Concurrent Coverage of Palliative, Curative Care

AJMC Staff

Instead of making patients suffering from life-limiting illnesses choose between hospice care and curative care, CMS will test coverage that allows individuals to receive palliative and curative treatment concurrently.

July 20th 2015

Researchers Use Precision Medicine in Common Type of Lymphoma

Laura Joszt, MA

In the first clinical study to demonstrate the importance of precision medicine in lymphomas, researchers determined that patients with a specific molecular subtype of diffuse large B-cell lymphoma responded better to ibrutinib than patients with a different molecular subtype.

July 20th 2015

Phase 3 Checkmate-025, Evaluating Nivolumab in RCC, Stopped Early

AJMC Staff

Nivolumab proved superior to everolimus in improving overall survival in previously treated patients.

July 19th 2015

Cancer Gene May Be Linked to Obesity

Laura Joszt, MA

A gene known to cause cancer may also play a role in determining obesity, according to researchers at the Virginia Commonwealth University Massey Cancer Center.

July 17th 2015

Patient Advocates Demand Oral Parity in North Carolina

AJMC Staff

The demand for oral parity for oncology medications is back up for vote in the Senate in North Carolina.

July 16th 2015

Elotuzumab Combo Delays Myeloma Progression in Phase 3 Trial

Jason M. Broderick

A presscast held prior to the annual meeting of the American Society of Clincal Oncology presented interim results from the phase 3 ELOQUENT-2 trial. Adding elotuzumab to lenalidomide and dexamethasone reduced the risk of disease progression by 30% in patients with relapsed-refractory multiple myeloma.

July 16th 2015

Annual Report on the Status of Cancer in the United States Released

AJMC Staff

The Annual Report to the Nation on Status of Cancer, product of a collaboration between The American Cancer Society, Centers for Disease Control and Prevention, National Cancer Institute, and North American Association of Central Cancer Registries, has been published.

July 16th 2015

Choosing Wisely? Increased Radiation Does Not Improve Survival Outcomes in Low-Risk Prostate Cancer

Surabhi Dangi-Garimella, PhD

A study published in JAMA Oncology questions aggressive local treatment strategies in men with low-risk prostate cancer.

July 16th 2015

Choosing the Ideal Lymphoma Regimens

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Clinical Oncology in Chicago, physicians introduced some new lymphoma treatments as they described their personal experience with using them during the session, "Incorporating Novel Agents Into Lymphoma Therapy: Value in Everyday Practice."

July 16th 2015

Novel Options in Melanoma and Multiple Myeloma

Surabhi Dangi-Garimella, PhD

Immuno-oncology continues to deliver results in oncology, as seen from results presented at the annual meeting of the American Society of Clinical Oncology. The combination of nivolumab and ipilimumab significantly improved survival in melanoma, while elotozumab showed encouraging results in relapsed refractory multiple myeloma.

July 16th 2015

Predictive Biomarkers Present Promise in Immuno-Oncology

Surabhi Dangi-Garimella, PhD

A late-breaking abstract session early at the annual meeting of the American Society of Clinical Oncology presented datd for nivolumab in the treatment of hepatocellular carcinoma, non-squamous cell non-small cell lung cancer, and for tumors harboring mismatch repair deficiency.

July 16th 2015

ACA-Mandated Elimination of Cost Sharing for Preventive Screening Has Had Limited Early Impact

Shivan J. Mehta, MD, MBA Daniel Polsky, PhD Jingsan Zhu, MBA James D. Lewis, MD, MSCE Jonathan T. Kolstad, PhD George Loewenstein, PhD Kevin G. Volpp, MD, PhD

The ACA eliminated patient cost sharing for evidence-based preventive care, yet this policy has not resulted in substantial increases in colonoscopy and mammography utilization.

July 16th 2015

Jennifer Malin, MD, Discusses Challenges Facing Payers in Medical Oncology

Jennifer Malin, MD, medical director for oncology at Anthem, explains how both physicians and payers struggle with the high cost of some cancer treatment drugs.

July 15th 2015

Oncologists Inspect the Costs and Quality of Cancer Care

Surabhi Dangi-Garimella, PhD

During the session "Health Services Research and Quality of Care" at the annual meeting of the American Society of Clinical Oncology, oncologists discussed factors that influence clinical trial participation and the cost of cancer care.

July 15th 2015

Young Adult Cancer Survivors Face Long-Term Complications After Remission

Cate Douglass

Young adult cancer survivors who had received their first rounds of cancer treatment between the ages of 20 and 44 were 1.5 times more likely to have more hospitalizations after remission than the general public.

July 15th 2015

Linda House Looks at the Cost of Cancer Care Holistically

Taking into account all of the factors a patient may be dealing with is 1 way to address the growing cost of cancer care and its associated problems, like medication or treatment nonadherence.

July 15th 2015

Stakeholder Definition of Value in Cancer: Where Are We 1 Year Later?

Surabhi Dangi-Garimella, PhD

July 15th 2015

A Balancing Act: Oncologist Explains the Impact of Physician Administrative Burdens

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Clinical Oncology, Robin Zon, MD, discussed the growing administrative burdens in oncology practice with the movement towards value-based payment.

July 14th 2015

Screening Colonoscopy Can Reduce Mortality, Study Finds

AJMC Staff

The retrospective study, conducted in centers across Germany, found that when colorectal cancer was detected during a screening colonoscopy, patients lived nearly 2 years longer than if it was detected during a diagnostic colonoscopy.

July 13th 2015

Phase 3 RECOURSE Trial Holds Promise for Colorectal Cancer

Surabhi Dangi-Garimella, PhD

A poster presented at the 2015 annual meeting of the American Society of Clinical Oncology shared encouraging phase 3 survival data from the RECOURSE trial, after evaluating specific geographic subgroups.

...

123 124 125 126 127 128 129 130 131

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions